Reolysin Doubles Survival Rates of P53-mutated Metastatic Breast Cancer Patients Receiving Taxol, Study Finds

Reolysin Doubles Survival Rates of P53-mutated Metastatic Breast Cancer Patients Receiving Taxol, Study Finds
Women with mutated p53 metastatic breast cancer lived twice as long when treated with Reolysin plus Taxol (paclitaxel) compared to those who received Taxol alone, according to the randomized, IND 213 Phase 2 trial (NCT01656538). Vanessa Bernstein of the British Columbia Cancer Agency in Vancouver presented the study's findings in a poster, "A Randomized (RCT) Phase II Study of Oncolytic Reovirus (Pelareorep) plus Standard Weekly Paclitaxel (P) as Therapy for Metastatic Breast Cancer (mBC)," at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. "Mutations of the p53 tumor suppressor gene play an increasingly challenging role throughout the life cycle of cancer," Matt Coffey, MD, president and CEO of Oncolytics, said in a press release. "As breast cancer progresses clinically, p53 mutations become more prominent and negatively impact therapeutic efficacy and overall survival. These data provide evidence that combining Reolysin with paclitaxel may improve survival for this difficult-to-treat, well characterized patient population." Reolysin is a proprietary formulation of the human reovirus that replicates specifically inside cancer cells, leading to their death. By releasin
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.